Outcomes and Costs in Patients with Immune Thrombotic Thrombocytopenic Purpura Receiving Front-Line Versus Delayed Caplacizumab: A US Hospital Database Study
Clinical and Applied Thrombosis/Hemostasis · 2024
DOI: 10.1177/10760296241241525 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, 2024. Verfasst von Alix Arnaud und 7 weiteren Autor:innen. Beteiligte Einrichtung: Sanofi, Boston, MA, USA. Hauptthemen laut MEDLINE: Purpura, Thrombotic Thrombocytopenic, Single-Domain Antibodies, Purpura, Thrombocytopenic, Idiopathic, Thrombosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi.
Abstract (Originalsprache)
European real-world data indicate that front-line treatment with caplacizumab is associated with improved clinical outcomes compared with delayed caplacizumab treatment. The objective of the study was to describe the characteristics, treatment patterns, and outcomes in hospitalized patients with an immune-mediated thrombotic thrombocytopenic purpura (iTTP) episode treated with front-line versus delayed caplacizumab in the US. This retrospective cohort analysis of a US hospital database included adult patients (≥18 years) with an acute iTTP episode (a diagnosis of thrombotic microangiopathy and ≥1 therapeutic plasma exchange [TPE] procedure) from January 21, 2019, to February 28, 2021. Unadjusted baseline characteristics, treatment patterns, healthcare resource utilization, and costs were compared between patients who received front-line versus delayed (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sanofi, Boston, MA, USA.
- Aetion, Inc., New York, NY, USA.
- Sanofi, Lisbon, Portugal.
- Sanofi, São Paulo, Brazil.
- Sanofi K.K., Tokyo, Japan.
ORCID-Profile: Alix Arnaud, Jackie Lucia
Förderung
- Sanofi
Zitieren
APA
Arnaud, A., Schilsky, S., Lucia, J., Maia, M., Laredo, F., Marques, A. P., Okada, H., & Roberts, A. W. (2024). Outcomes and Costs in Patients with Immune Thrombotic Thrombocytopenic Purpura Receiving Front-Line Versus Delayed Caplacizumab: A US Hospital Database Study. Clinical and Applied Thrombosis/Hemostasis. https://doi.org/10.1177/10760296241241525
Vancouver
Arnaud A, Schilsky S, Lucia J, Maia M, Laredo F, Marques AP, et al. Outcomes and Costs in Patients with Immune Thrombotic Thrombocytopenic Purpura Receiving Front-Line Versus Delayed Caplacizumab: A US Hospital Database Study. Clinical and Applied Thrombosis/Hemostasis. 2024. doi:10.1177/10760296241241525
BibTeX
@article{Arnaud2024,
author = {Arnaud, Alix and Schilsky, Samantha and Lucia, Jackie and Maia, Marta and Laredo, Fernando and Marques, Ana Paula and Okada, Hikaru and Roberts, Andrew W},
title = {Outcomes and Costs in Patients with Immune Thrombotic Thrombocytopenic Purpura Receiving Front-Line Versus Delayed Caplacizumab: A US Hospital Database Study},
journal = {Clinical and Applied Thrombosis/Hemostasis},
year = {2024},
doi = {10.1177/10760296241241525}
}
EUVIMED